Reprint

Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry

Edited by
April 2024
232 pages
  • ISBN978-3-7258-0859-5 (Hardback)
  • ISBN978-3-7258-0860-1 (PDF)

This book is a reprint of the Special Issue Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Neurodegeneration is a major problem in neuroscience and medicine, as it causes and worsens many neurological and psychiatric disorders. It involves gradually losing neurons at different brain levels, affecting cognition, emotion, behavior, consciousness, and attention. However, the current therapies are mostly symptomatic and ineffective. In light of these limitations, there is an urgent need to develop novel and transformative approaches, among which non-invasive brain stimulation (NIBS) holds considerable promise. NIBS techniques can modulate neural activity and safely and reversibly promote plasticity, presenting an avenue for exploring innovative treatment modalities. Moreover, the NIBS field is evolving rapidly, with ongoing research endeavors to elucidate its mechanisms of action, identify new clinical applications, and investigate synergistic interactions with pharmacological agents. This Special Issue covers the latest progress and challenges in studying neurodegeneration in cognitive impairment and mood disorders from experimental, clinical, and translational perspectives. It addresses the complexities and diversity of these conditions, the scarcity of disease-modifying treatments, the ethical and practical challenges of conducting research in the development and validation of novel methods such as NIBS, artificial intelligence, and drug repurposing. Collaborative efforts among various stakeholders are needed to improve our knowledge and treatment of neurodegenerative, underlying cognitive impairment, and mood disorders.

Format
  • Hardback
License
© 2024 by the authors; CC BY-NC-ND license
Keywords
saliva; cortisol; biomarker; depression; prediction; level; collection; methods; correction; blood; doxorubicin; drug combination; drug repurposing; MCF-7 cells; SH-SY5Y cells; atorvastatin; nitrofurantoin; depression; anxiety; rapid-acting effect; essential oil; glutamate; neurotoxicity; neuroinflammation; post-traumatic stress disorder; dementia; Parkinson’s disease; β-amyloid; inflammation; hippocampus; white matter integrity; genetics; astrocyte; glial cells; xanthine; oxidative stress; free radicals; neurodegenerative; caffeine; cognition; multiple sclerosis; processing speed of information; attention; memory; nanoparticles; metal; neuropsychological tests; biomarkers; blood; schizophrenia; resistant schizophrenia; working memory; attention; fixation; reproduction; disorganized symptoms; dissociation; short-term memory; working memory; Down syndrome; neurodevelopment; cognitive impairment; comorbidity; diagnosis; management; artificial intelligence; machine learning; neurological disorders; intellectual disability; mercury (Hg); autism spectrum disorder (ASD); clinical matrices; comprehensive meta-analysis; stroke; lacunar; mendelian randomization analysis; drug repurposing; antihypertensive agent; hypolipidemic agents; hypoglycemic agents; aging; healthy; precision medicine; genetic association studies; preventive medicine; cognitive dysfunction; neurobehavioural function; neurodegenerative diseases; neuroinflammation; anxiety; depression; learning and memory; sensorimotor function; locomotion; cognitive impairment; symbiotic; cerebral ischemia; BDNF; TNF-α; tMCAO; Enterococcus faecium; cytokines; neuroprotection; memory; n/a